KPRX stock Statistics — Kiora Pharmaceuticals INC filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-05 · filed common shares: 4.42M
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 0.08%
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 19.60%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 24.30%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin (nine months)Nine months: 2024-01-01 to 2024-09-30 · Not annualized: 44.16%
Net margin: —
EBITDA margin (nine months)Nine months: 2024-01-01 to 2024-09-30 · Not annualized: 44.25%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -56.36%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -39.43%

Cash & equivalentsas of Jun 26: $7.07M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $333.02K
Debt / equityas of Jun 26: 1.98%
Current ratioas of Jun 26: 8.97
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Jun 26: 7.56
Operating cash flowTTM to Jun 26: -$8.50M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$8.61M
TTM revenue / diluted share: —